GlassScriptPhysician profile
Alexander Kirshenbaum
NPI 1447306345
$971.48
in general payments reported to CMS, 2019-2025
12 companies · $35.06 in 2025
The $35.06 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $222 · 2021: $25.79 · 2022: $23.61 · 2023: $214 · 2024: $196 · 2025: $35.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.24 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $355.40 | 2023-2024 | Urolift |
| Medtronic USA, INC. | $225.25 | 2019-2020 | |
| Procept Biorobotics Corporation | $120.46 | 2019-2020 | |
| Janssen Biotech, INC. | $61.45 | 2022-2023 | Erleada |
| Pfizer INC. | $55.39 | 2019-2020 | |
| Neotract INC. | $41.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $19.01 | 2019 | |
| Urogen Pharma, INC. | $17.00 | 2024 | |
| Abbvie INC. | $15.00 | 2019 | |
| Astellas Pharma US INC | $14.53 | 2021 | |
| Olympus America INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kirshenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.